Coles, A J <br/><br/>
Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis.  [electronic resource] 

 -  Annals of neurology  Sep 1999 
 - 296-304 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0364-5134 
<br/><br/><label>Standard No.: </label>10.1002/1531-8249(199909)46:3<296::aid-ana4>3.0.co;2-#  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Alemtuzumab<br/>Antibodies, Monoclonal--therapeutic use<br/>Antibodies, Monoclonal, Humanized<br/>Antibodies, Neoplasm--therapeutic use<br/>Enzyme-Linked Immunosorbent Assay<br/>Humans<br/>Inflammation--pathology<br/>Magnetic Resonance Imaging<br/>Multiple Sclerosis--pathology<br/>Time Factors<br/>Tumor Necrosis Factor-alpha--analysis